Daraxonrasib Side Effects: What the FDA Label and Trials Show
Daraxonrasib (Rasonque) can cause rash, diarrhea and mouth sores, with rarer serious risks. Compare FDA-label data with the first-line combination trial.
Reporting on pancreatic cancer research, treatments and patient outcomes, including what clinical trial data can and cannot establish about new therapies.
Daraxonrasib (Rasonque) can cause rash, diarrhea and mouth sores, with rarer serious risks. Compare FDA-label data with the first-line combination trial.
Who can receive daraxonrasib for metastatic pancreatic cancer under US and EU approvals, and how UK patients can ask about clinical trial access.
New data on daraxonrasib plus chemotherapy show a 60.7% response rate in 61 patients. What the trial proves, its limits and whether the regimen is approved.